Zhejiang Medicine Co., Ltd. (SHA:600216)
China flag China · Delayed Price · Currency is CNY
12.33
-0.28 (-2.22%)
Sep 24, 2026, 3:00 PM CST

Zhejiang Medicine Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,9048,8349,3367,7628,0739,088
Other Revenue
40.3946.2338.7632.1143.2341.3
8,9448,8819,3757,7948,1169,129
Revenue Growth
-3.75%-5.28%20.29%-3.96%-11.10%24.60%
Cost of Revenue
6,0865,9845,5915,3925,4385,530
Gross Profit
2,8582,8963,7852,4022,6783,599
Selling, General & Admin
1,4501,4091,6781,4811,3121,546
Research & Development
512.83579.88749.35860.07809.28806.86
Other Operating Expenses
59.3751.3753.8552.369.8675.17
Operating Expenses
2,0222,0372,4942,3942,1882,439
Operating Income
836.18859.521,2917.98489.741,160
Interest Expense
-24.1-24.82-26.37-28.34-33.11-39.54
Interest & Investment Income
67.6332.7222.5116.5113.1857.42
Currency Exchange Gain (Loss)
-105.0274.9717.8236.5966.6-64.31
Other Non Operating Income (Expenses)
-7.75-5.23.921.09-36.73-2.69
EBT Excluding Unusual Items
766.94937.21,30853.83499.671,111
Impairment of Goodwill
---18.68-9.23-8.12-
Gain (Loss) on Sale of Investments
25.914.64-29.6-28.59-56.5151.73
Gain (Loss) on Sale of Assets
-5.92-6.56-5.21323.57-1.37-7.95
Asset Writedown
-25.62-25.62-69.41---46.19
Other Unusual Items
51.2542.0726.7723.6957.7144.76
Pretax Income
812.56951.731,212363.28491.391,154
Income Tax Expense
161.33191.49192.0386.48128.77268.97
Earnings From Continuing Operations
651.23760.241,020276.79362.61884.56
Minority Interest in Earnings
154.86113.14140.26152.85176.96160.76
Net Income
806.09873.381,161429.64539.571,045
Net Income to Common
806.09873.381,161429.64539.571,045
Net Income Growth
-46.91%-24.74%170.11%-20.37%-48.38%45.71%
Shares Outstanding (Basic)
953955959955964959
Shares Outstanding (Diluted)
954955959955964959
Shares Change
-0.83%-0.42%0.46%-0.91%0.47%0.26%
EPS (Basic)
0.850.911.210.450.561.09
EPS (Diluted)
0.840.911.210.450.561.09
EPS Growth
-46.82%-24.79%168.89%-19.64%-48.62%45.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,0301,439534.15-162.56-455.39197.05
Free Cash Flow Per Share
1.081.510.56-0.17-0.470.20
Dividend Per Share
0.2800.2800.3700.1500.1700.330
Dividend Growth
-24.32%-24.32%146.67%-11.77%-48.48%43.48%
Gross Margin
31.95%32.61%40.37%30.82%33.00%39.43%
Operating Margin
9.35%9.68%13.77%0.10%6.03%12.71%
Profit Margin
9.01%9.84%12.38%5.51%6.65%11.45%
Free Cash Flow Margin
11.52%16.21%5.70%-2.09%-5.61%2.16%
EBITDA
1,5151,5692,013732.171,1711,747
EBITDA Margin
16.94%17.67%21.47%9.39%14.42%19.14%
D&A For EBITDA
679.21709.85721.94724.19680.81586.79
EBIT
836.18859.521,2917.98489.741,160
EBIT Margin
9.35%9.68%13.77%0.10%6.03%12.71%
Effective Tax Rate
19.85%20.12%15.84%23.81%26.21%23.32%
Revenue as Reported
8,9448,8819,3757,7948,1169,129
Advertising Expenses
-9.4518.4621.2519.5921.3